Ask AI
ProCE Banner Activity

ALNEO: Phase II Trial of Perioperative Alectinib in Potentially Resectable Stage III ALK-Positive NSCLC

Conference Coverage
Slideset

In the phase II ALNEO clinical trial, neoadjuvant treatment with alectinib in patients with stage III ALK-positive NSCLC met the primary endpoint of improving major pathologic response in potentially resectable tumors with no unexpected safety signals.

Released: June 04, 2025

Expiration: December 03, 2025

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo, Inc, Genentech, a member of the Roche Group, and PharmaMar.

AstraZeneca

Boehringer Ingelheim Pharmaceuticals, Inc.

Daiichi Sankyo, Inc.

Genentech, a member of the Roche Group

PharmaMar